Beat COVID trial of Acalabrutinib in patients with blood cancer and covid infection
Latest Information Update: 15 Sep 2020
At a glance
- Drugs Acalabrutinib (Primary)
- Indications Acute myeloid leukaemia; Aplastic anaemia; COVID 2019 infections; Lymphoma; Myelodysplastic syndromes; Myeloma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Acronyms Beat COVID
- 15 Sep 2020 New trial record
- 09 Sep 2020 According to The Leukemia & Lymphoma Society, the trial has been launched by The Leukemia & Lymphoma Society (LLS).
- 09 Sep 2020 According to The Leukemia & Lymphoma Society, Michael Boyiadzis, MD, of the University of Pittsburg is the principal investigator of this study